← Back to news
NewsEXPERT OPIN DRUG DISCOVThursday, March 26, 2026 · March 26, 2026

The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery

WHY IT MATTERS

Recent peer-reviewed research relevant to rare disease diagnosis or treatment.

Published in Expert Opin Drug Discov. Ruchi R et al.

Read on PubMed →
Read the original at Expert Opin Drug Discov ↗
ResearchPubMed

Related conditions

Spinal muscular atrophy associated with central nervous system anomalySpinal muscular atrophy with respiratory distress type 2Spinal muscular atrophy with respiratory distress type 1Homozygous familial hypercholesterolemiaDuchenne muscular dystrophy

Related news

Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…